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Summary
Freeman has considered the following two-stage procedure for finding a confidence
interval for the treatment difference theta, using data from an AB/BA crossover
trial. In the first stage, a preliminary test of the null hypothesis that the differential
carryover is zero, is carried out. If this hypothesis is accepted then the confidence
interval for theta is constructed assuming that the differential carryover is zero.
If, on the other hand, this hypothesis is rejected then this confidence interval is
constructed using only data from the first period. Freeman has shown that this con-
fidence interval has minimum coverage probability far below nominal. He therefore
concludes that this confidence interval should not be used. In the present paper,
we analyse the performance of a similar two-stage procedure for an ABAB/BABA
crossover trial. This trial differs in very significant ways from an AB/BA crossover
trial, including the fact that for an ABAB/BABA crossover trial there is an unbiased
estimator of the differential carryover that is unaffected by between-subject varia-
tion. Despite these great differences, we arrive at the same conclusion as Freeman.
Namely, that the confidence interval resulting from the two-stage procedure should
not be used.
Key words: crossover trials; differential carryover; preliminary hypothesis test; two-
stage procedure.
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1. Introduction
Consider a two-treatment two-period crossover trial, with continuous responses.
The purpose of this trial is to find a 1−α confidence interval for the difference θ in
the effects of two treatments, labelled A and B. Subjects are randomly allocated to
either group 1 or group 2. Subjects in group 1 receive treatment A in the first pe-
riod and then receive treatment B in the second period. Subjects in group 2 receive
treatment B in the first period and then receive treatment A in the second period.
This trial is called an AB/BA trial. To deal with the possibility of non-zero differ-
ential carryover, it was suggested (starting with Grizzle, 1965, 1974 and endorsed
by Hills & Armitage, 1979 and Armitage & Hills, 1982) that the following two-stage
procedure be used. In the first stage, a preliminary test of the null hypothesis that
the differential carryover is zero (against the alternative that it is non-zero) is car-
ried out. If this null hypothesis is accepted then the confidence interval for θ is
constructed to have nominal coverage 1 − α, assuming that there is no differential
carryover. If, on the other hand, this null hypothesis is rejected then this confidence
interval is constructed using only data from the first period (since this is unaffected
by carryover). As pointed out by Freeman (1989), accepting this null hypothesis is
not equivalent to concluding that the differential carryover is exactly zero. Freeman
(1989) shows that the confidence interval interval resulting from this two-stage pro-
cedure has minimum coverage probability far below 1− α, demonstrating that this
confidence interval should not be used. Senn (2006) states “In my opinion the most
important paper on cross-over trials in the 25 years of Statistics in Medicine is Peter
Freeman’s paper”
What is the performance of this type of two-stage procedure for other crossover
designs? Jones & Kenward (2003, pp. 123–125) analyse the performance of this
type of procedure for Balaam’s design. This analysis makes the following two as-
sumptions. The first assumption is that any carryover from a treatment in a given
period is only into the next period, and not beyond (“first-order carryover” model).
The second assumption is that the carryover from one period into the next period is
determined only by the treatment applied in the first period and not the treatment
applied in the second period. Thus, for example, according to this second assump-
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tion the carryover from treatment A into the next period is the same, irrespective
of whether the treatment in the next period is A or B. This assumption has rightly
been criticized as being unrealistic by Fleiss (1986, 1989), Senn & Lambrou (1998)
and Senn (2001, 2002, 2005). This severely limits the applicability of the analysis
of Jones & Kenward (2003) of this type of procedure for Balaam’s design.
In the present paper we consider an ABAB/BABA crossover trial. Subjects
are randomly allocated to either group 1 or group 2. Subjects in group 1 receive
treatments A, B, A and B in the first, second, third and fourth periods respectively.
Subjects in group 2 receive treatments B, A, B and A in the first, second, third and
fourth periods respectively. We assume that any carryover from a treatment in a
given period is only into the next period, and not beyond. However, our analysis
of this trial does not require us to assume that the carryover from one period into
the next period is determined only by the treatment applied in the first period and
not the treatment applied in the second period. This is because we never need to
consider the carryover of a treatment from one period into the next period for which
the same treatment is applied. Two major differences between the AB/BA and
ABAB/BABA trials are the following. For an ABAB/BABA trial:
(i) There is an unbiased estimator (which is unaffected by differential carryover)
of θ that has the following properties. It is unaffected by the between-subject
variation. Also, it is obtained without ignoring all of the data from periods 2,
3 and 4. This is the estimator Θˆ described in Section 2.
(ii) There is an unbiased estimator of the differential carryover that is unaffected
by the between-subject variation. This is the estimator Ψˆ described in Section
2.
There are two arguments against the adoption of Θˆ as the standard estimator of
θ. Firstly, as shown in Appendix A, this estimator is inefficient by comparison with
the usual estimator of θ based on data from a completely randomized design, using
the same number of measurements of the response, unless a restrictive condition
holds. Secondly, there is an estimator of θ, which we denote by A and describe
in Section 2, that is much more efficient than Θˆ, when the differential carryover is
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zero. We view Θˆ as the analogue for an ABAB/BABA design of the estimator of θ
constructed using only data from the first period of an AB/BA design.
To deal with the possibility of non-zero differential carryover, it is tempting to
consider the use of the following two-stage procedure. In the first stage a prelimi-
nary test of the null hypothesis that the differential carryover is zero (against the
alternative that it is non-zero) is carried out. If this null hypothesis is accepted
then the confidence interval for θ is constructed using the estimator A (described in
Section 2) and having nominal coverage 1−α, assuming that there is no differential
carryover. If, on the other hand, this null hypothesis is rejected then this confi-
dence interval is constructed to have nominal coverage 1 − α, using the estimator
Θˆ (described in Section 2) that is based on data from all 4 periods. This two-stage
procedure is described in detail in Section 2.
A computationally-convenient formula for the coverage probability of the confi-
dence interval that results from this procedure is presented in Section 2. In Section
3 we numerically evaluate the coverage properties of this confidence interval. We
show that this confidence interval has minimum coverage probability far below 1−α,
demonstrating that this confidence interval should not be used. The coverage prob-
ability of this confidence interval depends only on the scaled differential carryover.
This is in sharp contrast to the coverage probability of the confidence interval re-
sulting from the two-stage procedure applied to data from an AB/BA trial, found
by Freeman (1989), which depends on both the scaled differential carryover and the
ratio (error variance)/(subject variance).
Beginning with the work of Freeman (1989), the literature on the effect of prelim-
inary model selection (using, for example, hypothesis tests or minimizing a criterion
such as AIC or Mallows’s CP ) on confidence intervals has grown steadily. This lit-
erature is reviewed by Kabaila (2009). It is commonly the case that preliminary
model selection has a highly detrimental effect on the coverage probability of these
confidence intervals. However, each case needs to be considered individually on its
merits.
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2. The two-stage analysis of ABAB/BABA trials under
consideration
We assume the following model for the ABAB/BABA trial. This model is sim-
ilar to the model for an AB/BA crossover trial put forward by Grizzle (1965), as
described by Grieve (1987). Let n1 and n2 denote the number of subjects in group
1 and group 2 respectively. Also let Yijk be the response of the jth subject in the
ith group and the kth period (i = 1, 2; j = 1, . . . , ni; k = 1, 2, 3, 4). The model is
Yijk = µ+ ξij + πk + φℓ + λq + εijk (1)
where
µ is the overall population mean
ξij is the effect of the jth subject in the ith group
πk is the effect of the kth period
φℓ is the effect of the ℓth treatment
λq is the residual effect of the qth treatment
εijk is the random error
Note that both ℓ and q are determined by the group i and the period k. This model
is described in less abbreviated form in Appendix A. We assume that the ξij and εijk
are independent and that the ξij are identically N(0, σ
2
s) distributed and the εijk are
identically N(0, σ2ε) distributed, where σ
2
s > 0 and σ
2
ε > 0. Let m = (1/n1)+(1/n2).
The parameter of interest is θ = φ1 − φ2. The parameter describing the differ-
ential carryover effect is ψ = 3(λ1 − λ2)/4. Let Y¯i·k = (1/ni)
∑ni
j=1 Yijk (i = 1, 2;
k = 1, 2, 3, 4). We reduce that data to D1, D2, D3, D4, where D1 = Y¯1·1 − Y¯2·1,
D2 = Y¯1·2− Y¯2·2, D3 = Y¯1·3− Y¯2·3 and D4 = Y¯1·4− Y¯2·4. The motivation for this data
reduction is presented in Appendix A. Let
A =
1
4
(D1 −D2 +D3 −D4).
This is the usual estimator of θ, when it is assumed that ψ = 0 (see e.g. Table I of
Senn & Lambrou, 1998). Let
Θˆ = D1 − 1
4
D2 − 1
2
D3 − 1
4
D4.
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This is an unbiased estimator (which is unaffected by differential carryover) of θ that
is unaffected by between-subject variation (cf Table I of Senn & Lambrou, 1998).
We will use Θˆ as the estimator of θ when it cannot be assumed that necessarily
ψ = 0. We view Θˆ as the analogue for an ABAB/BABA design of the estimator of θ
constructed using only data from the first period of an AB/BA design. As shown in
Appendix A, Θˆ is inefficient by comparison with the usual estimator of θ based on
data from a completely randomized trial, using the same number of measurements
of response, unless σ2s ≥ 4.5 σ2ε . We will also make use of the following unbiased
estimator of ψ:
Ψˆ =
3
4
(D1 −D3).
As shown in Appendix B, these statistics have the following distributions: A ∼
N(θ − ψ,mσ2ε/4), Θˆ ∼ N(θ, 11mσ2ε/8) and Ψˆ ∼ N(ψ, 9mσ2ε/8). Note that when
ψ = 0, A is a much more efficient estimator of θ than Θˆ.
To deal with the possibility of non-zero differential carryover, it is tempting to
consider the use of the following two-stage procedure. In the first stage a preliminary
test of the null hypothesis that ψ = 0 (against the alternative that ψ 6= 0) is carried
out, using a test statistic based on Ψˆ. If this null hypothesis is accepted then the
confidence interval for θ is constructed using the estimator A and having nominal
coverage 1 − α, assuming that ψ = 0. If, on the other hand, this null hypothesis is
rejected then this confidence interval is constructed to have nominal coverage 1−α,
using the estimator Θˆ.
To analyse the properties of this two-stage procedure, we make the simplification
that σ2ε is known. Freeman (1989) makes the same simplification. So, in the first
stage, we test the null hypothesis H0 : ψ = 0 against the alternative hypothesis
H1 : ψ 6= 0 using the test statistic
√
8/9m Ψˆ/σε. This test statistic has an N(0, 1)
distribution under H0. Define the quantile ca by the requirement that P (−ca ≤ Z ≤
ca) = 1 − a for Z ∼ N(0, 1). The following is a test of H0 against H1, with level
of significance α1. Accept H0 if
∣∣√8/9m Ψˆ/σε∣∣ < cα1 ; otherwise reject H0. In the
second stage we proceed as follows. If H0 is accepted then we construct a confidence
interval for θ, with nomimal coverage 1− α, assuming that ψ = 0. This confidence
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interval is [
A− cα
√
m/4 σε, A+ cα
√
m/4σε
]
. (2)
If, on the other hand, H0 is rejected then we do not assume that ψ = 0 and we
construct a confidence interval for θ, with nomimal coverage 1 − α, based on Θˆ.
This confidence interval is
[
Θˆ− cα
√
11m/8σε, Θˆ + cα
√
11m/8σε
]
. (3)
Let J denote the confidence interval for θ that results from this two-stage proce-
dure. Also let γ =
√
8/9mψ/σε. As shown in Appendix A, the coverage probability
of the confidence interval J is
P (θ ∈ J) = P (|H| < cα1)P (|X| ≤ cα)+ P (|G| ≤ cα, |H| ≥ cα1), (4)
where [
G
H
]
∼ N
([
0
γ
]
,
[
1 3/
√
11
3/
√
11 1
])
(5)
andX ∼ N(−3γ/√2 , 1). Note that, for given α1 and α, the coverage probability (4)
is a function of the scaled differential carryover γ. The right-hand side of (4) is easily
computed (using e.g. R or MATLAB programs), for each given γ. The last term on
the right-hand side of (4) can be computed by evaluating the cumulative distribution
function of the bivariate normal distribution (5). Alternatively, this term can be
computed by numerically evaluating the integral (11), derived in Appendix C.
3. Numerical evaluation of the coverage probability as a
function of γ
Consider the two-stage procedure, for an AB/BA trial, based on a preliminary
test with given level of significance and resulting in a confidence interval with a given
nominal coverage. As shown by Freeman (1989), the actual coverage probability of
this confidence interval depends on both the scaled differential carryover
(
λ
√
n/σ
in Freeman’s notation
)
and ρ = σ2s/(σ
2
ε + σ
2
s). For each different value of ρ, there is
a different graph of this coverage probability as a function of the scaled differential
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carryover. The larger the value of ρ, the smaller the minimum coverage probability
of this confidence interval.
Now consider the two-stage procedure described in the previous section, for an
ABAB/BABA trial, based on a preliminary test with given level of significance and
resulting in a confidence interval with a given nominal coverage. In sharp contrast
to the AB/BA trial, the actual coverage probability (given by (4)) of this confidence
interval depends only on the scaled differential carryover γ. This coverage is un-
influenced by the between-subject variability (which is described by the parameter
σ2s ). For level of significance α1 = 0.1 of the preliminary test and nominal coverage
1− α = 0.95, this coverage probability as a function of γ is shown in Figure 1. The
minimum coverage probability of this confidence interval is 0.4711, showing that this
confidence interval is completely inadequate. The minimum coverage probability of
this confidence interval was computed for a wide range of values of α1 and 1−α. In
every case, this confidence interval was found to have minimum coverage probability
far below nominal, showing that it is completely inadequate. Note that for a given
level of significance α1 of the preliminary test and given nominal coverage 1 − α,
the minimum coverage probability of this confidence interval does not depend on
either of the sample sizes n1 and n2. The only effect of an increase in n1 and n2 is to
change the scaling (via m = (1/n1) + (1/n2)) of the differential carryover ψ. Con-
sequently, the harmful effect of preliminary hypothesis testing does not disappear
with an increase in sample sizes n1 and n2.
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Figure 1: Plot of the coverage probability of the confidence interval for θ, resulting
from the two-stage procedure, against γ. This confidence interval has nominal cov-
erage 1− α = 0.95. The preliminary hypothesis test has significance level α1 = 0.1.
The horizontal dashed line has vertical axis intercept 0.95.
4. Conclusion
For an ABAB/BABA trial, we have shown that the minimum coverage proba-
bility of the confidence interval resulting from the two-stage procedure is far below
the nominal coverage, showing that this confidence interval is completely inade-
quate. Increasing the sample sizes n1 and n2 does not improve the situation. Our
conclusion is that this confidence interval should not be used. This is similar to
the conclusion of Freeman (1989) for confidence intervals resulting from a two-stage
procedure applied to an AB/BA trial. In other words, we provide further support
for the rejection by Senn (2002, p.12) of analyses of data from any two-treatment
crossover trial based on a preliminary test of the null hypothesis that the differential
carryover is zero.
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Appendix A: The efficiency of Θˆ by comparison with an
estimator from a completely randomized trial
In this appendix, we consider the efficiency of Θˆ by comparison with the usual es-
timator of θ based on data from a completely randomized trial. For an ABAB/BABA
crossover trial, the total number of measurements of the response is 4(n1 + n2). We
therefore compare Θˆ with the usual estimator of θ based on data from a completely
randomized trial, with 2(n1 + n2) randomly-chosen subjects in each group.
Let Y A1 , . . . , Y
A
2(n1+n2)
denote the responses of the 2(n1 + n2) subjects given
treatment A. Also let Y B1 , . . . , Y
B
2(n1+n2)
denote the responses of the 2(n1 + n2)
subjects given treatment B. Consistently with the model (1), we suppose that
Y A1 , . . . , Y
A
2(n1+n2)
, Y B1 , . . . , Y
B
2(n1+n2)
are independent random variables, where
Y A1 , . . . , Y
A
2(n1+n2)
are identically N
(
µ+φ1, σ
2
ε+σ
2
s
)
distributed and Y B1 , . . . , Y
B
2(n1+n2)
are identically N
(
µ+ φ2, σ
2
ε + σ
2
s
)
distributed. The usual estimator of θ is
Θ˜ =
1
2(n1 + n2)
(
Y A1 + · · ·Y A2(n1+n2)
)− 1
2(n1 + n2)
(
Y B1 + · · ·Y A2(n1+n2)
)
.
This estimator has an N
(
θ, (σ2ε+σ
2
s)/(n1+n2)
)
distribution. Suppose, for simplicity,
that n1 = n2 = n. Thus Var(Θ˜) = (σ
2
ε + σ
2
s )/(2n) and Var(Θˆ) = 11σ
2
ε/(4n). Thus
Var(Θˆ) ≤ Var(Θ˜) if and only if σ2s ≥ 4.5 σ2ε .
Appendix B: Details for Section 2
This appendix consists of 3 sections. In the first section, we carry out data
reduction. In the second section, we derive the distributions of the statistics A, Θˆ
and Ψˆ. In the third section, we derive the formula (4) for the coverage probability
of the confidence interval J resulting from the two-stage procedure.
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Data reduction
It follows from the model (1) that
Y1j1 = µ+ ξ1j + π1 + φ1 + ε1j1
Y1j2 = µ+ ξ1j + π2 + φ2 + λ1 + ε1j2
Y1j3 = µ+ ξ1j + π3 + φ1 + λ2 + ε1j3
Y1j4 = µ+ ξ1j + π4 + φ2 + λ1 + ε1j4
Y2j1 = µ+ ξ2j + π1 + φ2 + ε2j1
Y2j2 = µ+ ξ2j + π2 + φ1 + λ2 + ε2j2
Y2j3 = µ+ ξ2j + π3 + φ2 + λ1 + ε2j3
Y2j4 = µ+ ξ2j + π4 + φ1 + λ2 + ε2j4
Let Y¯i·k = (1/ni)
∑ni
j=1 Yijk (i = 1, 2; k = 1, 2, 3, 4). We first reduce the data to Y¯1·1,
Y¯1·2, Y¯1·3, Y¯1·4, Y¯2·1, Y¯2·2, Y¯2·3 and Y¯2·4. Note that
Y¯1·1 = µ+ ξ¯1· + π1 + φ1 + ε¯1·1
Y¯1·2 = µ+ ξ¯1· + π2 + φ2 + λ1 + ε¯1·2
Y¯1·3 = µ+ ξ¯1· + π3 + φ1 + λ2 + ε¯1·3
Y¯1·4 = µ+ ξ¯1· + π4 + φ2 + λ1 + ε¯1·4
Y¯2·1 = µ+ ξ¯2· + π1 + φ2 + ε¯2·1
Y¯2·2 = µ+ ξ¯2· + π2 + φ1 + λ2 + ε¯2·2
Y¯2·3 = µ+ ξ¯2· + π3 + φ2 + λ1 + ε¯2·3
Y¯2·4 = µ+ ξ¯2· + π4 + φ1 + λ2 + ε¯2·4
where ξ¯i· = (1/ni)
∑ni
j=1 ξij and ε¯i·k = (1/ni)
∑ni
j=1 εijk. Note that ξ¯1·, ξ¯2·, ε¯1·1, . . . , ε¯1·4,
ε¯2·1, . . . , ε¯2·4 are independent, ξ¯1· ∼ N(0, σ2s/n1), ξ¯2· ∼ N(0, σ2s/n2), ε¯1·1, . . . , ε¯1·4 are
identically N(0, σ2ε/n1) distributed and ε¯2·1, . . . , ε¯2·4 are identically N(0, σ
2
ε/n2) dis-
tributed.
The only way to remove the influence of the parameters π1, . . . , π4 on the reduced
data Y¯1·1, Y¯1·2, . . . , Y¯2·4 is to perform a further data reduction to D1, . . . , D4, where
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D1 = Y¯1·1 − Y¯2·1, D2 = Y¯1·2 − Y¯2·2, D3 = Y¯1·3 − Y¯2·3 and D4 = Y¯1·4 − Y¯2·4. Note that
D1 = ξ¯1· − ξ¯2· + θ + η1
D2 = ξ¯1· − ξ¯2· − θ + 4
3
ψ + η2
D3 = ξ¯1· − ξ¯2· + θ − 4
3
ψ + η3
D2 = ξ¯1· − ξ¯2· − θ + 4
3
ψ + η4
where η1 = ε¯1·1− ε¯2·1, η2 = ε¯1·2− ε¯2·2, η3 = ε¯1·3− ε¯2·3 and η4 = ε¯1·4− ε¯2·4. Note that
η1, . . . , η4 are independent and identically N(0, mσ
2
ε ) distributed.
Derivation of the distributions of the statistics A, Θˆ and Ψˆ
Note that
A = θ − ψ + 1
4
(η1 − η2 + η3 − η4). (6)
Thus A ∼ N(θ − ψ,mσ2ε/4). Note that
Θˆ = θ + η1 − 1
4
η2 − 1
2
η3 − 1
4
η4 (7)
and that
Ψˆ = ψ +
3
4
(η1 − η3). (8)
It follows from (6) and (8) that (A, Ψˆ) has a bivariate normal distribution and that
Cov(A, Ψˆ) = 0. Thus A and Ψˆ are independent random variables. It follows from
(7) and (8) that [
Θˆ
Ψˆ
]
∼ N
([
θ
ψ
]
,
mσ2ε
8
[
11 9
9 9
])
. (9)
Derivation of the formula (4) for the coverage probability
Define the event
B =
{∣∣∣∣∣
√
8
9m
Ψˆ
σε
∣∣∣∣∣ < cα1
}
.
If this event occurs then J is equal to (2) and if Bc occurs then J is equal to (3).
By the law of total probability, the coverage probability P (θ ∈ J) is equal to
P
(
B ∩ {θ ∈ J})+ P (Bc ∩ {θ ∈ J})
= P
(
B ∩
{∣∣∣∣∣(A− θ)σε
√
4
m
∣∣∣∣∣ ≤ cα
})
+ P
(
Bc ∩
{∣∣∣∣∣(Θˆ− θ)σε
√
8
11m
∣∣∣∣∣ ≤ cα
})
= P (B)P
(∣∣∣∣∣(A− θ)σε
√
4
m
∣∣∣∣∣ ≤ cα
)
+ P
(
Bc ∩
{∣∣∣∣∣(Θˆ− θ)σε
√
8
11m
∣∣∣∣∣ ≤ cα
})
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since A and Ψˆ are independent random variables. Now define
γ =
√
8
9m
ψ
σε
, H =
√
8
9m
Ψˆ
σε
, G =
(Θˆ− θ)
σε
√
8
11m
and X =
(A− θ)
σε
√
4
m
.
Thus, the coverage probability P (θ ∈ J) is given by (4). Note that it follows from
(9) that the distribution of (G,H) is given by (5).
Appendix C: Alternative expression for
P
(
|G| ≤ cα, |H| ≥ cα1
)
In this appendix, we present an alternative expression for P
(|G| ≤ cα, |H| ≥ cα1)
that may be convenient for the computation of the coverage probability (4). By the
law of total probability,
P
(|G| ≤ cα) = P (|G| ≤ cα, |H| ≥ cα1)+ P (|G| ≤ cα, |H| < cα1),
so that
P
(|G| ≤ cα, |H| ≥ cα1) = P (|G| ≤ cα)− P (|G| ≤ cα, |H| < cα1)
= 1− α− P (|G| ≤ cα, |H| < cα1)
since G ∼ N(0, 1).
Let fG,H(g, h) denote the probability density function of (G,H), evaluated at
(g, h). Also, let fH|G(h|g) denote the probability density function of H conditional
on G = g, evaluated at h. Let φ denote the N(0, 1) probability density function.
Observe that
P
(|G| ≤ cα, |H| < cα1) =
∫ cα
−cα
∫ cα1
−cα1
fG,H(g, h) dh dg
=
∫ cα
−cα
∫ cα1
−cα1
fH|G(h|g) dh φ(g) dg (10)
It follows from (5) that the distribution of H conditional on G = g is N
(
µ(g), v
)
,
where µ(g) = γ + (3g/
√
11) and v = 2/11. Thus (10) is equal to∫ cα
−cα
(
Φ
(
cα1 ;µ(g), v
)− Φ(− cα1 ;µ(g), v)) φ(g) dg (11)
where Φ(x;µ, v) denotes the N(µ, v) cumulative distribution function, evaluated at
x. The integral (11) is readily evaluated using the numerical quadrature functions
available in either R or MATLAB.
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